Tiziana Life Sciences PLC (TILS) Receives Speculative Buy Rating from Beaufort Securities

Beaufort Securities reaffirmed their speculative buy rating on shares of Tiziana Life Sciences PLC (LON:TILS) in a research note issued to investors on Friday.

Tiziana Life Sciences PLC (LON:TILS) traded up 0.30% during mid-day trading on Friday, hitting GBX 185.55. The stock had a trading volume of 1,309 shares. The company’s 50 day moving average is GBX 190.69 and its 200-day moving average is GBX 158.97. Tiziana Life Sciences PLC has a 52 week low of GBX 91.35 and a 52 week high of GBX 232.95. The stock’s market capitalization is GBX 172.16 million.

About Tiziana Life Sciences PLC

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. The Company is engaged in the research and development of biotechnological and pharmaceutical products. Its subsidiary, Tiziana Pharma Limited (TPL), is formed as a vehicle to acquire and exploit certain intellectual property in biotechnology, specifically a program focused on metastatic breast cancer.

Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.